Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

How these variables are influenced by long-term somatropin therapy in adults with childhood onset GH-deficiency has not been precisely defined.

Who Took Part

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Adrenocorticotropic Hormone, Catecholamines, Exercise, Growth Disorders, Hemodynamics, Hormones and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1998 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.